Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. - Wikidata - wikimedia - TriplyDB

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

http://www.wikidata.org/entity/Q33777535

about

Management of intracerebral hemorrhage--use of statins Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Anti-dementia medications: current prescriptions in clinical practice and new agents in progress Immunotherapy for Alzheimer's disease: hoops and hurdles Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease Genetic heterogeneity in Alzheimer disease and implications for treatment strategies Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Immunotherapeutic approaches for Alzheimer's disease APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective Neuroinflammation in Alzheimer's disease Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging.DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.White matter changes in dementia: role of impaired drainage of interstitial fluid.Imaging endpoints for clinical trials in Alzheimer's disease.Cerebral amyloid angiopathy: emerging concepts Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials.First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.Future Directions in Imaging Neurodegeneration.Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study.Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease.Novel immunological approaches for the treatment of Alzheimer's disease.An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion.Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.Specific amyloid β clearance by a catalytic antibody construct.Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

P2860

Q26752952-EA8C9504-A0DE-4FE0-8878-6EDABBDDDACE Q26781451-EA3561ED-D191-4263-B9A2-E4F926A493B0 Q26784569-2C70CFA1-A2E5-4FA1-8825-776A5E426427 Q26795400-AD2314D8-A802-4ABB-B317-414CA9E5F3A7 Q26823877-7DDF8ACB-87CE-46ED-AAEC-14E32B9C3880 Q26829899-52AE2F7A-FEBC-4093-8E52-0ADB46332D5F Q26995802-9A1C95B0-7CD8-4A8C-83C4-39A5341AE5C6 Q27684692-FF7037AA-3098-4107-B720-6EFA9381C961 Q28005463-D5AE93C5-C3A4-4021-A5F3-5B1F5572AEB1 Q28081278-2AA07AEF-B2FA-446F-B8B8-D7BC4D7FF338 Q28085213-73C58AB2-EFC6-46D3-9D1E-C6937231CA44 Q28259238-41229C3C-9980-4B73-9C07-60B7A1293456 Q28488690-37C9ADAB-70FD-4C26-B8C7-1D5E700669E9 Q30316057-868EC454-3E26-45B5-B08B-736E3E37583A Q30354417-584C64F5-A4EC-4342-A131-A98F21072C76 Q30412535-A65D490C-7323-4387-A637-79613012636A Q30651551-334E7BD8-64ED-4E76-9E61-38F7B5A4A1F8 Q30880445-9439C8CE-5A3D-4314-9BA3-3F9EE932A76A Q30885979-4722281D-D723-4408-AFCE-E4C19C232AE4 Q30894798-69B9F712-0C56-48CC-B2D1-509942A523DD Q30981669-A94534E7-4B46-449F-B690-13BCB51F26F1 Q30996733-ACDEA7F5-DBBF-4143-AE8F-393A1E9BCFD5 Q31050126-83894E89-3D26-4230-BA53-7883A99A5909 Q31162702-CA7096C6-0BFD-40B8-BEA3-67ED70A3FEAB Q31171988-9A33A014-8EE7-4A34-AEBF-E828416A0137 Q33723082-02FF1F89-227E-4306-A0C3-C5C00FCC57F5 Q33972726-D5ED1B9D-5BFF-4EA8-A838-FC8E23132EFC Q34154830-9776D436-A0F5-4661-9E44-D2784829264A Q34157492-11639C72-338A-4E26-9348-AD8D9597839D Q34286389-1592A0EB-9D29-43FA-8D75-2E39D437B75A Q34419108-F6945905-CC50-4664-9747-7EA83729DFC4 Q34431008-67213E34-5391-4FB7-A898-338A743AE582 Q34528767-71C32716-0DE7-49A9-9F67-380F0A4EC072 Q34538592-BB4B8DF5-3C3B-4672-8E18-30394E6D12D1 Q34562675-7CF4811E-2624-46C5-A64E-03BDFC4912CA Q34597563-8ACB89C8-D2DE-491A-826F-7939A1D153F2 Q34629872-319FCADB-9B4F-4915-A391-C4FA42760310 Q35052443-17ED5016-6F6C-40BD-8F4E-68084E0D5F20 Q35451085-E6A5223E-B840-44DF-AE3F-CF6B1F92C8EC Q35540628-15B82AFC-38D3-48D8-8ADC-72D333858B7B

P2860

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

http://www.wikidata.org/entity/Q33777535

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@ast

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@en

type

label

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@ast

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@en

prefLabel

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@ast

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@en

P1433

Q33777535-22DAAC19-9501-4AFB-AF4D-C45AFB2054B1

P1476

Q33777535-DD7BA472-D5B5-480F-BB0E-78649B8496FB

P2093

Q33777535-0561E2C6-43F1-4B64-A761-602C73920FB4

Q33777535-355319DE-7E3A-471D-9694-9BFCEBE7263C

Q33777535-3A18412A-65B1-49D7-8F5E-8E4ADE394B57

Q33777535-3C8ECFB9-2CCC-4E8C-BCAA-AB4191295302

Q33777535-3FFCD4F8-F11E-416C-8EA5-A291B8494C77

Q33777535-4142AC6C-B22B-454F-94C8-9C5ED15C6D55

Q33777535-614403FF-E5BF-4B90-9D6A-E945ECACC8DC

Q33777535-6ADDDDB9-596D-4245-9217-DCF67C40AA41

Q33777535-71AD9B68-2C90-4459-AD37-D29885C9B96F

Q33777535-7AD1208F-7152-4130-B055-230D00AA0E0A

P2860

Q33777535-014B06EC-46DA-4219-B7D3-96BCCC7479EE

Q33777535-38A99FD0-AE17-4B90-8C99-9397D2CE77D0

Q33777535-57E39323-3766-4209-9B11-BE157949F7DF

Q33777535-5E450FAD-EFFC-4DDD-9145-08FE1A15206D

Q33777535-5ED62A2F-6DDF-479F-8C3A-D45D3782102B

Q33777535-658175A2-5875-4F90-A107-529E0EE1366F

Q33777535-6B1E03D9-F2E8-426E-8D32-1CDE1B50CA06

Q33777535-6BCA4983-52F8-42D7-970B-1F37B05F932C

Q33777535-71B62272-5FFB-430C-8B59-B40250080217

Q33777535-74BA210F-E31C-4052-9394-4D8BA57E0751

P304

Q33777535-C2AC233C-96FA-4D1A-8BF1-7815C7A84F6E

P31

Q33777535-5024B6C3-2B60-4129-97D2-577578AEF4E1

P356

Q33777535-74205B9F-0F85-4030-BFCF-2A8FFDCFE628

P433

Q33777535-BD710E42-8F43-43B0-A1AC-2BBA62A5E5C9

P478

Q33777535-FCC79D4E-2BD0-4AB1-99AD-CD176401CF55

P50

Q33777535-A2099C8B-5B01-4A78-A01F-1347BF9298FE

Q33777535-CE715333-B2E2-45E7-9E4F-B446308ACD6E

Q33777535-FC045F12-FAEC-42F9-88E2-F51FF27442FA

P577

Q33777535-2CD9277C-0979-4702-9DED-AEEA3A7ADF26

P698

Q33777535-3C59E5CB-AEC1-4312-A525-4CB163BA304D

P921

Q33777535-2DEDA546-A069-42C4-A72B-D08F73E6A9FA

P932

Q33777535-F0C8AB49-6381-410E-B048-B191773E371F

P356

S1474-4422(12)70015-7

P1433

Lancet Neurology

P1476

Amyloid-related imaging abnorm ...... mab: a retrospective analysis.

@en

P2093

Anton P Porsteinsson

http://www.w3.org/2001/XMLSchema#string

Donatella Tampieri

http://www.w3.org/2001/XMLSchema#string

Enchi Liu

http://www.w3.org/2001/XMLSchema#string

Gene G Kinney

http://www.w3.org/2001/XMLSchema#string

H Michael Arrighi

http://www.w3.org/2001/XMLSchema#string

H Robert Brashear

http://www.w3.org/2001/XMLSchema#string

Ivan Lieberburg

http://www.w3.org/2001/XMLSchema#string

Jerome Barakos

http://www.w3.org/2001/XMLSchema#string

Keith M Gregg

http://www.w3.org/2001/XMLSchema#string

Kristen A Morris

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy

Amyloid load in nondemented brains correlates with APOE e4.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

P304

241-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(12)70015-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

David J. Brooks

P577

2012-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22305802

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4063417

http://www.w3.org/2001/XMLSchema#string